BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sainz-Mejías M, Jurado-Martín I, McClean S. Understanding Pseudomonas aeruginosa-Host Interactions: The Ongoing Quest for an Efficacious Vaccine. Cells 2020;9:E2617. [PMID: 33291484 DOI: 10.3390/cells9122617] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Killough M, Rodgers AM, Ingram RJ. Pseudomonas aeruginosa: Recent Advances in Vaccine Development. Vaccines (Basel) 2022;10:1100. [PMID: 35891262 DOI: 10.3390/vaccines10071100] [Reference Citation Analysis]
2 Kaya E, Batoni G, Di Luca M, Apolloni E, Mazzoni A, Maisetta G, Esin S. Planktonic and Biofilm-Associated Pseudomonas aeruginosa and Staphylococcus epidermidis Elicit Differential Human Peripheral Blood Cell Responses. Microorganisms 2021;9:1846. [PMID: 34576742 DOI: 10.3390/microorganisms9091846] [Reference Citation Analysis]
3 Ferrell KC, Johansen MD, Triccas JA, Counoupas C. Virulence Mechanisms of Mycobacterium abscessus: Current Knowledge and Implications for Vaccine Design. Front Microbiol 2022;13:842017. [DOI: 10.3389/fmicb.2022.842017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Reig S, Le Gouellec A, Bleves S. What Is New in the Anti–Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert? Front Cell Infect Microbiol 2022;12:909731. [DOI: 10.3389/fcimb.2022.909731] [Reference Citation Analysis]
5 Vos R, Van Herck A. Pseudomonas aeruginosa and chronic lung allograft dysfunction: does evading an iceberg prevent the ship from sinking? Eur Respir J 2021;58:2100041. [PMID: 34326173 DOI: 10.1183/13993003.00041-2021] [Reference Citation Analysis]
6 Howlader DR, Das S, Lu T, Hu G, Varisco DJ, Dietz ZK, Walton SP, Ratnakaram SSK, Gardner FM, Ernst RK, Picking WD, Picking WL. Effect of Two Unique Nanoparticle Formulations on the Efficacy of a Broadly Protective Vaccine Against Pseudomonas Aeruginosa. Front Pharmacol 2021;12:706157. [PMID: 34483911 DOI: 10.3389/fphar.2021.706157] [Reference Citation Analysis]
7 Gonzaga ZJC, Merakou C, DiGiandomenico A, Priebe GP, Rehm BHA. A Pseudomonas aeruginosa-Derived Particulate Vaccine Protects against P. aeruginosa Infection. Vaccines (Basel) 2021;9:803. [PMID: 34358220 DOI: 10.3390/vaccines9070803] [Reference Citation Analysis]
8 Jurado-Martín I, Sainz-Mejías M, McClean S. Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. Int J Mol Sci 2021;22:3128. [PMID: 33803907 DOI: 10.3390/ijms22063128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
9 Rahbar MR, Mubarak SMH, Hessami A, Khalesi B, Pourzardosht N, Khalili S, Zanoos KA, Jahangiri A. A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseudomonas aeruginosa. Sci Rep 2022;12:10852. [PMID: 35760825 DOI: 10.1038/s41598-022-14877-5] [Reference Citation Analysis]
10 Sousa SA, Seixas AMM, Marques JMM, Leitão JH. Immunization and Immunotherapy Approaches against Pseudomonas aeruginosa and Burkholderia cepacia Complex Infections. Vaccines (Basel) 2021;9:670. [PMID: 34207253 DOI: 10.3390/vaccines9060670] [Reference Citation Analysis]
11 Cairns CM, Michael FS, Jamshidi M, van Faassen H, Yang Q, Henry KA, Hussack G, Sauvageau J, Vinogradov EV, Cox AD. Structural Characterization and Evaluation of an Epitope at the Tip of the A-Band Rhamnan Polysaccharide of Pseudomonas aeruginosa. ACS Infect Dis 2022. [PMID: 35653593 DOI: 10.1021/acsinfecdis.2c00183] [Reference Citation Analysis]
12 Gonzaga ZJC, Zhang J, Rehm BHA. Intranasal Delivery of Antigen-Coated Polymer Particles Protects against Pseudomonas aeruginosa Infection. ACS Infect Dis 2022;8:744-56. [PMID: 35238554 DOI: 10.1021/acsinfecdis.1c00434] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]